Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus

Overview

Journal Diabetes Metab J

Specialty Endocrinology

Date 2016 Oct 22

PMID 27766241

Citations 25

Authors

Sung-Ho Kim

Jung-Hwa Yoo

Woo Je Lee

Cheol-Young Park

Affiliations

Soon will be listed here.

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral antidiabetic agent for the treatment of type 2 diabetes mellitus. They increase endogenous levels of incretin hormones, which stimulate glucose-dependent insulin secretion, decrease glucagon secretion, and contribute to reducing postprandial hyperglycemia. Although DPP-4 inhibitors have similar benefits, they can be differentiated in terms of their chemical structure, pharmacology, efficacy and safety profiles, and clinical considerations. Gemigliptin (brand name: Zemiglo), developed by LG Life Sciences, is a potent, selective, competitive, and long acting DPP-4 inhibitor. Various studies have shown that gemigliptin is an optimized DPP-4 inhibitor in terms of efficacy, safety, and patient compliance for treatment of type 2 diabetes mellitus. In this review, we summarize the characteristics of gemigliptin and discuss its potential benefits in clinical practice.

Citing Articles

Financial Benefits of Renal Dose-Adjusted Dipeptidyl Peptidase-4 Inhibitors for Patients with Type 2 Diabetes and Chronic Kidney Disease.

Choe H, Ko Y, Moon S, Ahn C, Ha K, Lee H Endocrinol Metab (Seoul). 2024; 39(4):622-631.

PMID: 39086276 PMC: 11375300. DOI: 10.3803/EnM.2024.1965.

Selective targeting of dipeptidyl-peptidase 4 (DPP-4) positive senescent chondrocyte ameliorates osteoarthritis progression.

Ro D, Cho G, Kim J, Min S, Yang H, Park H Aging Cell. 2024; 23(7):e14161.

PMID: 38556837 PMC: 11258469. DOI: 10.1111/acel.14161.

Gemigliptin, a potent selective dipeptidyl peptidase 4 inhibitor, protects endothelial progenitor cells by oxidative stress via caspase-3 dependent pathway.

Lee M, Tariq A, Kim M Biochem Biophys Rep. 2024; 38:101673.

PMID: 38444735 PMC: 10914559. DOI: 10.1016/j.bbrep.2024.101673.

A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and....

Kim H, Noh J, Moon M, Choi S, Ko S, Rhee E J Diabetes Res. 2024; 2024:8915591.

PMID: 38223523 PMC: 10787050. DOI: 10.1155/2024/8915591.

Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition.

Xie Y, Zhou Q, He Q, Wang X, Wang J Acta Pharm Sin B. 2023; 13(6):2383-2402.

PMID: 37425060 PMC: 10326166. DOI: 10.1016/j.apsb.2022.11.008.

References

Pratley R, Fleck P, Wilson C . Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes Metab. 2014; 16(7):613-21. DOI: 10.1111/dom.12258. View

Bosi E, Dotta F, Jia Y, Goodman M . Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009; 11(5):506-15. DOI: 10.1111/j.1463-1326.2009.01040.x. View

Hong S, Park C, Han K, Chung C, Ku B, Jang H . Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial. Diabetes Obes Metab. 2016; 18(5):528-32. PMC: 5069603. DOI: 10.1111/dom.12631. View

Kim S, Lee S, Yim H . Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry. Arch Pharm Res. 2013; 36(10):1185-8. DOI: 10.1007/s12272-013-0171-x. View

DeFronzo R, Hissa M, Garber A, Gross J, Yuyan Duan R, Ravichandran S . The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009; 32(9):1649-55. PMC: 2732156. DOI: 10.2337/dc08-1984. View

Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle H . Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2012; 14(6):565-74. DOI: 10.1111/j.1463-1326.2012.01590.x. View

Kim Y, Kim U, Kim I, Lee S, Lee J, Kim D . Absorption, distribution, metabolism and excretion of gemigliptin, a novel dipeptidyl peptidase IV inhibitor, in rats. Xenobiotica. 2014; 44(7):627-34. DOI: 10.3109/00498254.2013.873156. View

Lukashevich V, Del Prato S, Araga M, Kothny W . Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes Metab. 2013; 16(5):403-9. PMC: 4237555. DOI: 10.1111/dom.12229. View

Charbonnel B, Karasik A, Liu J, Wu M, Meininger G . Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006; 29(12):2638-43. DOI: 10.2337/dc06-0706. View

10.

Del Prato S, Barnett A, Huisman H, Neubacher D, Woerle H, Dugi K . Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011; 13(3):258-67. DOI: 10.1111/j.1463-1326.2010.01350.x. View

11.

Min H, Kim J, Lee M, Song H, Kang Y, Lee M . Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction. Lab Invest. 2014; 94(6):598-607. DOI: 10.1038/labinvest.2014.50. View

12.

Duran-Garcia S, Lee J, Yki-Jarvinen H, Rosenstock J, Hehnke U, Thiemann S . Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes. Diabet Med. 2015; 33(7):926-33. DOI: 10.1111/dme.13041. View

13.

Barnett A, Charbonnel B, Donovan M, Fleming D, Chen R . Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin. 2012; 28(4):513-23. DOI: 10.1185/03007995.2012.665046. View

14.

Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M . Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35(6):1364-79. PMC: 3357214. DOI: 10.2337/dc12-0413. View

15.

. Standards of medical care in diabetes--2014. Diabetes Care. 2013; 37 Suppl 1:S14-80. DOI: 10.2337/dc14-S014. View

16.

Pi-Sunyer F, Schweizer A, Mills D, Dejager S . Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract. 2007; 76(1):132-8. DOI: 10.1016/j.diabres.2006.12.009. View

17.

Kim N, Patrick L, Mair S, Stevens L, Ford G, Birks V . Absorption, metabolism and excretion of [14C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Xenobiotica. 2013; 44(6):522-30. DOI: 10.3109/00498254.2013.865856. View

18.

Owens D, Swallow R, Dugi K, Woerle H . Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med. 2011; 28(11):1352-61. DOI: 10.1111/j.1464-5491.2011.03387.x. View

19.

DeFronzo R, Fleck P, Wilson C, Mekki Q . Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008; 31(12):2315-7. PMC: 2584188. DOI: 10.2337/dc08-1035. View

20.

Rosenstock J, Rendell M, Gross J, Fleck P, Wilson C, Mekki Q . Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 2009; 11(12):1145-52. DOI: 10.1111/j.1463-1326.2009.01124.x. View